These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12848736)

  • 1. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.
    Turner PJ; Greenhalgh JM;
    Clin Microbiol Infect; 2003 Jun; 9(6):563-7. PubMed ID: 12848736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S; Garcia-Rodriguez JA
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.
    Dueñas Díez AI; Bratos Pérez MA; Eiros Bouza JM; Almaraz Gómez A; Gutiérrez Rodríguez P; Miguel Gómez MA; Orduña Domingo A; Rodríguez-Torres A
    Int J Antimicrob Agents; 2004 May; 23(5):487-93. PubMed ID: 15120728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).
    Turner PJ
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):291-3. PubMed ID: 15582303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
    Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
    Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
    Marti S; Sánchez-Céspedes J; Alba V; Vila J
    Int J Antimicrob Agents; 2009 Feb; 33(2):181-2. PubMed ID: 18977642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem resistance in Acinetobacter baumannii: where is it heading?
    Deveci Ö; Dal T; Tekin R; Bozkurt F; Tekin A; Dayan S
    Infez Med; 2013 Sep; 21(3):211-5. PubMed ID: 24008854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
    Rhomberg PR; Jones RN; Sader HS;
    Int J Antimicrob Agents; 2004 Jan; 23(1):52-9. PubMed ID: 14732314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.